Rick Huntress, Director Business Development
Clinical and In Vivo Services, The Jackson Laboratory
Eileen Geoghegan, Ph.D.,
Research Fellow, Albert Einstein College of Medicine
Criteria that investors and companies use to evaluate drugs for licensing or acquisition can be different from those used by reviewers and journals for publication. In this webinar, we will discuss strategies that allow researchers to anticipate such concerns and generate the kind of data that investors appreciate. The session will help early-career researchers, engineers, and data-scientists navigate the complex process of engaging their supporters.
“When a researcher or company enters into an agreement with a licensee or investor, the valuation of their underlying capabilities, intellectual property, and market potential drives the deal,” says presenter Rick Huntress.
“Experienced investors and companies value research that demonstrates a drug response, and helps to de-risk their investments from the traditional points of failure,” he says. “Unfortunately, it is still true that majority of drugs fail to move into the clinic after licensing.”
At the nonprofit Jackson Laboratory, Rick Huntress works directly with researchers, sponsors, engineers, and data scientists to design and execute early stage drug efficacy evaluations. The Jackson Laboratory's mission is to discover precise genomic solutions for disease and empower the global biomedical community in the shared quest to improve human health.
Eileen Geoghegan, Ph.D., Research Fellow at the Albert Einstein College of Medicine, and a member of WBP’s Scientific Advisory Board, will moderate. She is a Johns Hopkins University and National Institutes of Health trained scientist with a demonstrated ability to design, construct, and evaluate novel recombinant antibody-based therapeutics.
Host: Joanne Gere, Executive Director, Westchester Biotech Project
Associate: Christopher Kinzel, Associate for Communication, Westchester Biotech Project